GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio filed a prospectus supplement registering 5,450,774 shares of common stock issuable upon exercise of previously issued Series E-1, E-2, E-3, pre-funded, and placement agent warrants, offered on a continuous basis under Rule 415. The related “reasonable best efforts” offering—covering 202,000 common shares, 1,186,888 pre-funded warrants, 1,388,888 Series E-1 warrants, 1,388,888 Series E-2 warrants, 1,388,888 Series E-3 warrants, and 97,222 placement agent warrants—was completed on April 2, 2025.
Alongside, the company reported quarterly results: cash and cash equivalents were $4.055 million as of September 30, 2025. Net loss was $3.359 million for the quarter and $9.297 million year-to-date, driven by research and development of GRI-0621 and higher general and administrative costs. The company noted substantial doubt about its ability to continue as a going concern based on current resources.
Shares outstanding were 3,268,727 as of November 13, 2025. GRI-0621’s Phase 2a biomarker study in idiopathic pulmonary fibrosis completed enrollment in July 2025, with topline results expected by the end of November 2025.
GRI Bio, Inc. filed its Q3 2025 10-Q, reporting a quarterly net loss of $3,359 on operating expenses of $3,365 (both in thousands). Cash and cash equivalents were $4,055, with management stating resources are sufficient into the first quarter of 2026 and disclosing substantial doubt about the ability to continue as a going concern without additional financing.
Year to date, operating cash use was $7,215, partially offset by financing inflows, including $5,000 from April 2025 offering proceeds and $2,560 through the ATM program (gross, in thousands). The company increased additional paid-in capital to $51,030 and ended the quarter with stockholders’ equity of $1,993 (in thousands). As of November 13, 2025, 3,268,727 common shares were outstanding.
GRI continues a Phase 2a biomarker study of GRI-0621 in IPF, with topline results expected by the end of November 2025. The pipeline also includes GRI-0803, with further progress dependent on funding.
GRI Bio, Inc. (GRI) reported an insider derivative transaction by Chief Financial Officer Leanne Kelly. The filing shows an award of a stock option covering 43,222 shares with an exercise price of $1.93. The option is exercisable immediately and expires in 2035. Of the options, 29,923 vested in full at grant and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary. The reporting person holds these options directly following the transaction.
GRI Bio, Inc. reporting person David Leslie Szekeres received a stock option award totaling 39,897 shares exercisable at $1.93. The options were granted and reported with a transaction date of 09/18/2025, become exercisable immediately for 29,293 shares and for the remaining 9,974 shares vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of grant. The options expire on 09/18/2035 and are reported as direct beneficial ownership, leaving 39,897 shares underlying the option beneficially owned after the transaction.
GRI Bio, Inc. (GRI) director David Charles Baker was granted a stock option on 09/18/2025 to buy 23,605 shares of common stock at a $1.93 exercise price. The option becomes exercisable on 09/18/2025 and expires on 09/18/2035. Of the total, 17,621 options vested immediately on the grant date and 5,984 options will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The Form 4 was filed by a single reporting person and signed via attorney-in-fact on 09/22/2025.
GRI Bio insider option grant: Director Camilla V. Simpson was granted a stock option on 09/18/2025 to buy 23,605 shares of GRI Bio common stock at a $1.93 exercise price. Of the option, 17,621 shares vested immediately on the grant date and 5,984 shares will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The option expires on 09/18/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/22/2025.
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio director Roelof Rongen reported a stock option grant that became partially vested on 09/18/2025. The filing shows options to purchase 23,605 shares of common stock at an exercise price of $1.93 per share, exercisable through 09/18/2035. Following the grant, Mr. Rongen beneficially owns 23,605 option shares directly. Of those options, 17,621 vested immediately on the grant date and 5,984 will vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of the grant date.
The Form 4 was filed as a single reporting person filing and bears a signature dated 09/22/2025 by an attorney-in-fact.
GRI Bio, Inc. (GRI) reporting person Walter Marc Hertz, identified as Director and Chief Executive Officer, was granted a stock option award on 09/18/2025 covering 103,067 shares with an exercise price of $1.93 per share. The award is exercisable through 09/18/2035. Under the grant, 76,469 options vested in full on the grant date and the remaining 26,598 options vest in 12 substantially equal quarterly installments, completing on the third anniversary of the grant. The Form 4 was signed by an attorney-in-fact on 09/22/2025. The filing shows direct beneficial ownership of the options and does not include additional cash compensation or other transaction types.
Walter Marc Hertz, identified as Chief Executive Officer and a director of GRI Bio, Inc. (GRI), reported on Form 4 a transaction dated 08/26/2025 involving stock options. He acquired 26,688 shares of common stock by exercising options with an exercise price of $1.41 per share. Of the options, 17,828 vested in full on the grant date and 8,860 will vest in 12 substantially equal quarterly installments, with the option fully vested on the third anniversary of the grant date. Following the transaction, Mr. Hertz beneficially owns 26,688 shares directly. The filing is signed by an attorney-in-fact, Leanne Kelly.